Literature DB >> 33572160

Post-Translational Modifications That Drive Prostate Cancer Progression.

Ivana Samaržija1.   

Abstract

While a protein primary structure is determined by genetic code, its specific functional form is mostly achieved in a dynamic interplay that includes actions of many enzymes involved in post-translational modifications. This versatile repertoire is widely used by cells to direct their response to external stimuli, regulate transcription and protein localization and to keep proteostasis. Herein, post-translational modifications with evident potency to drive prostate cancer are explored. A comprehensive list of proteome-wide and single protein post-translational modifications and their involvement in phenotypic outcomes is presented. Specifically, the data on phosphorylation, glycosylation, ubiquitination, SUMOylation, acetylation, and lipidation in prostate cancer and the enzymes involved are collected. This type of knowledge is especially valuable in cases when cancer cells do not differ in the expression or mutational status of a protein, but its differential activity is regulated on the level of post-translational modifications. Since their driving roles in prostate cancer, post-translational modifications are widely studied in attempts to advance prostate cancer treatment. Current strategies that exploit the potential of post-translational modifications in prostate cancer therapy are presented.

Entities:  

Keywords:  SUMOylation; acetylation; glycosylation; lipidation; phosphorylation; post-translational modification; prostate cancer; ubiquitination

Mesh:

Year:  2021        PMID: 33572160      PMCID: PMC7915076          DOI: 10.3390/biom11020247

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  437 in total

1.  SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells.

Authors:  Jung Hwa Kim; Ji Min Lee; Hye Jin Nam; Hee June Choi; Jung Woo Yang; Jason S Lee; Mi Hyang Kim; Su-Il Kim; Chin Ha Chung; Keun Il Kim; Sung Hee Baek
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

2.  Estrogen receptor β (ERβ1) transactivation is differentially modulated by the transcriptional coregulator Tip60 in a cis-acting element-dependent manner.

Authors:  Ming-Tsung Lee; Yuet-Kin Leung; Irving Chung; Pheruza Tarapore; Shuk-Mei Ho
Journal:  J Biol Chem       Date:  2013-07-15       Impact factor: 5.157

Review 3.  Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment.

Authors:  Gagan Deep; Gati K Panigrahi
Journal:  Crit Rev Oncog       Date:  2015

4.  ASC-J9® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3.

Authors:  WanYing Lin; Jie Luo; Yin Sun; ChangYi Lin; Gonghui Li; Yuanjie Niu; Chawnshang Chang
Journal:  Cancer Lett       Date:  2018-02-06       Impact factor: 8.679

Review 5.  Targeting Glycosylation: A New Road for Cancer Drug Discovery.

Authors:  Ana Filipa Costa; Diana Campos; Celso A Reis; Catarina Gomes
Journal:  Trends Cancer       Date:  2020-05-04

6.  HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

Authors:  Michael J Gray; Jing Zhang; Lee M Ellis; Gregg L Semenza; Douglas B Evans; Stephanie S Watowich; Gary E Gallick
Journal:  Oncogene       Date:  2005-04-28       Impact factor: 9.867

7.  Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells.

Authors:  Ceshi Chen; Xiaodong Sun; Peng Guo; Xue-Yuan Dong; Pooja Sethi; Xiaohong Cheng; Jun Zhou; Junxiu Ling; Jonathan W Simons; Jerry B Lingrel; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

8.  Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

Authors:  Johann S de Bono; Ugo De Giorgi; Daniel Nava Rodrigues; Christophe Massard; Sergio Bracarda; Albert Font; Jose Angel Arranz Arija; Kent C Shih; George Daniel Radavoi; Na Xu; Wai Y Chan; Han Ma; Steven Gendreau; Ruth Riisnaes; Premal H Patel; Daniel J Maslyar; Viorel Jinga
Journal:  Clin Cancer Res       Date:  2018-07-23       Impact factor: 12.531

9.  O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1.

Authors:  Hector F Valenzuela; Karen E Pace; Paula V Cabrera; Rachel White; Katja Porvari; Helena Kaija; Pirkko Vihko; Linda G Baum
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity.

Authors:  Teppei Okamoto; Mihoko Sutoh Yoneyama; Shingo Hatakeyama; Kazuyuki Mori; Hayato Yamamoto; Takuya Koie; Hisao Saitoh; Kanemitsu Yamaya; Tomihisa Funyu; Minoru Fukuda; Chikara Ohyama; Shigeru Tsuboi
Journal:  Mol Med Rep       Date:  2012-11-19       Impact factor: 2.952

View more
  5 in total

Review 1.  Glycosylation as a regulator of site-specific metastasis.

Authors:  Wendy E Bindeman; Barbara Fingleton
Journal:  Cancer Metastasis Rev       Date:  2021-12-30       Impact factor: 9.264

Review 2.  From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer.

Authors:  Ekaterina Nevedomskaya; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

3.  SUMOylation Regulator-Related Molecules Can Be Used as Prognostic Biomarkers for Glioblastoma.

Authors:  Xiaozhi Li; Yutong Meng
Journal:  Front Cell Dev Biol       Date:  2021-04-09

4.  Site-Specific and Common Prostate Cancer Metastasis Genes as Suggested by Meta-Analysis of Gene Expression Data.

Authors:  Ivana Samaržija
Journal:  Life (Basel)       Date:  2021-06-30

Review 5.  Unconventional protein post-translational modifications: the helmsmen in breast cancer.

Authors:  Jiena Liu; Qin Wang; Yujuan Kang; Shouping Xu; Da Pang
Journal:  Cell Biosci       Date:  2022-02-25       Impact factor: 7.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.